Buscar
Biontech SE
BNTXAñadir a la lista de seguimiento
91.220USD
+1.220+1.36%
Cierre 06/26, 16:00（ET）Cotizaciones retrasadas 15 min
23.07BCap. mercado
PérdidaP/E TTM
Más Datos de Biontech SE Compañía
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Información de Biontech SE
Símbolo de cotizaciónBNTX
Nombre de la empresaBiontech SE
Fecha de salida a bolsaOct 10, 2019
Director ejecutivoSahin (Ugur)
Número de empleados6772
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 10
DirecciónAn der Goldgrube 12
CiudadMAINZ
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísGermany
Código postal55131
Teléfono4949613190840
Sitio Webhttps://www.biontech.com/
Símbolo de cotizaciónBNTX
Fecha de salida a bolsaOct 10, 2019
Director ejecutivoSahin (Ugur)
Ejecutivos de Biontech SE
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
692.54K
-10.83%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
1.43K
+44.60%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Michael Motschmann
Mr. Michael Motschmann
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Michael Horowicz
Mr. Michael Horowicz
Director, Investor Relations
Director, Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
692.54K
-10.83%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
1.43K
+44.60%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Biontech SE?
Los cinco principales accionistas de Biontech SE son: Dr. Sierk Poetting, Ph.D.
¿Cuántas instituciones poseen acciones de Biontech SE (BNTX)?
A fecha de 2026Q1, 802 instituciones poseen acciones de Biontech SE, con un valor de mercado combinado de aproximadamente 51.86M, lo que representa el 20.51% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1292358.00.
¿Cuál es la mayor fuente de ganancias de Biontech SE?
El 2026Q1, el segmento empresarial Collaboration Revenue generó la ganancia más alta para Biontech SE, ascendiendo a 84.43M y representando el 77.75% de la ganancia total.
